Ascendis Pharma A/S (ASND)
NasdaqGS · Biotechnology
Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.
Price history
Daily closes and volumeAI Analysis Generated from the indicator readings below. Educational only.
Ascendis Pharma A/S is trading at $251.27, down 0.68% on the session. The 50 day average sits at $242.59 and the 200 day at $237.14, which puts the stock in a uptrend. RSI is at 59.5, which reads as strong, and MACD is bullish crossover. Volume is below average.
The nearest support is around $240.64 with resistance near $258.55, so that band frames the current range. Average daily movement is roughly $6.87, or about 2.7% of the share price, which is what any stop placement has to allow for. The overall health score of 77 out of 100 combines a trend score of 77, momentum of 80 and a risk score of 71.
Technical indicators
AI trade signals on ASND
All signals| Date | Setup | Entry | Target | Stop | R:R | Status |
|---|---|---|---|---|---|---|
| Sep 7 | Breakout | ••.•• | ••.•• | ••.•• | 2.02:1 | Stopped Out |
About Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Company website